24 Apr 2024 • Patients with T2DM and atherosclerosis are at high risk of limb events. Ticagrelor, when added to aspirin, significantly reduced limb events, particularly revascularization and acute limb ischemia (ALI).

Among patients with peripheral artery disease (PAD) at baseline, ticagrelor showed consistent benefits in reducing limb events, suggesting a potential role in this high-risk population.

However, ticagrelor increased bleeding risk, suggesting a careful consideration of the balance between benefits and risks in T2DM patients with atherosclerosis.

Source: JACC | Read full story